NIH R01 · 2024
Safety of Anti-CGRP Migraine Therapeutics in Ischemic Stroke
Small molecule calcitonin gene-related peptide (CGRP) receptor antagonists (“gepants”) and anti-CGRP or anti- CGRP-receptor monoclonal antibodies (“nezumabs”) are novel treatments for migraine. However, endogenous CGRP is among the most potent vasodilator molecules, and CGRP-mediated vasodilation is a critical rescue mechanism in cerebral ischemia. Therefore, CGRP antagonism may increase cerebrovascular event risk in migraineurs. Despite this obvious concern, the magnitude of unmet need in the migraine field has propelled the clinical development of CGRP antagonists despite case reports of vascular complications. We recently reported that gepants worsen the outcome after brief middle…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.